Using various CRC cell lines with different mutation statuses, we compared the effects of the WEE1 inhibitor adavosertib on cell proliferation, cell cycle, and apoptosis induction, especially focusing on p53 and KRAS mutations involved in the G1/S checkpoint. Here, KRAS is linked to colorectal carcinoma.